Stethophone™ Receives Full Approval for Use by Patients and Their Families in Ukraine

Ukraine clears breakthrough SaaMD that enables people to usetheir smartphones as clinical-grade devices that listen for cardiovascular disease at home

Sparrow BioAcoustics today announced it has received clearance from the State Service of Ukraine for Medicines and Drugs Control for its Stethophone™ app to be used by patients and their families, as well as by medical professioinals.

“Sparrow BioAcoustics is proud to receive its first full approval for patients to use Stethophone in Ukraine,” said Mark Opauszky, CEO of Sparrow. “Like many people, members of our team are close to Ukraine and neighboring countries in Eastern Europe. We wanted to be able to help patients in this nation. Like the U.S. Food and Drug Administration, the Ukrainian health authority is known for its high standards and strong focus on public safety.”

Earlier this year, the FDA granted clearance for Stethophone to be used by medical professionals and emergency medical technicians to monitor, record and share the sounds of the heart and lungs. In Sparrow’s clinical tests, Stethophone outperforms the class-leading traditional stethoscopes in cardiac and pulmonary auscultation.

Stethophone is a breakthrough Software as a Medical Device (SaaMD) app that enables smartphones to capture, isolate and evaluate the sounds of the heart and lungs simply by placing the microphone of a smartphone against a patient’s chest. The information is processed for both visual and auditory evaluation, and can be securely shared with other members of the care team. This makes Stethophone the clinical-grade stethoscope that is always with you, and can capture the sounds of symptoms whenever and wherever they occur.

The downloadable Stethophone™ application uses advanced acoustic processing to provide smartphones with highly sensitive cardiac and pulmonary listening capability. Stethophone is unique in that there is nothing new to plug in, charge, or connect. Heart and lung sounds are captured by simply holding a smartphone to a patient’s chest.

“There is a world of diagnostic information contained in chest sounds, and the healthcare system needs a practical way to capture this data and put it to work for the benefit of patients,” said Opauszky. “Stethophone is the tool to do this.”

In trials conducted at Eastern Health Medical Centre, Newfoundland, Canada, 70 percent of medical professionals rated Stethophone superior in diagnostic sound performance over other leading devices. Stethophone also performed significantly higher in overall correct heart pathology diagnosis and correct normal heart diagnosis.

Cardiovascular diseases (CVDs) are the leading cause of death globally, representing 32 percent of all global deaths. The number of people at risk of CVD is on the rise. The American heart association reports that nearly half of all U.S. adults have some type of cardiovascular disease.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”